Home > Products & Pipeline  |
Contact Us |
Glossary |
Site Map |
|
|
|||||
|
|
 |
|
|||
|
|
ABOUT VION | PRODUCTS & PIPELINE | CLINICAL TRIALS | INVESTOR RELATIONS |
|
|
|
 |
|
 Laromustine (Cloretazine®, VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, three clinical trials of laromustine (Cloretazine®, VNP40101M) are underway in: (i) elderly AML and myelodysplastic syndromes in combination with cytarabine; (ii) brain tumors in combination with temozolomide; and (iii) advanced hematologic malignancies in combination with hematopoietic cell transplantation. Triapine® is designed to prevent the replication of tumor cells by blocking ribonucleotide reductase, an enzyme critical to DNA synthesis and repair. Triapine® is in clinical trials sponsored by the National Cancer Institute.
|
|
| Privacy | Terms of Use | Copyright | ©2008 Vion Pharmaceuticals, Inc. |
|